Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Risk of Left Atrial POP Ablation and Esophageal Injury Under Ultra-High Power and Related Influencing Parameters

NCT06699368 is registered in ClinicalTrials.gov with The Third People's Hospital of Chengdu as lead sponsor.

NCT NCT06699368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06699368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Risk of Left Atrial POP Ablation and Esophageal Injury Under Ultra-High Power and Related Influencing Parameters
Lead sponsor
The Third People's Hospital of Chengdu
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 28, 2024
Completion date
June 5, 2025
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ultra-high power ablation,safety of atrial fibrillation ablation